These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25227893)

  • 1. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.
    Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW
    Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells.
    Moraya AI; Ali JL; Samadder P; Liang L; Morrison LC; Werbowetski-Ogilvie TE; Ogunsina M; Schweizer F; Arthur G; Nachtigal MW
    J Exp Clin Cancer Res; 2017 May; 36(1):67. PubMed ID: 28499442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
    Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
    Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
    Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
    Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
    Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
    Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
    Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
    Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
    Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
    Stringer-Reasor EM; Baker GM; Skor MN; Kocherginsky M; Lengyel E; Fleming GF; Conzen SD
    Gynecol Oncol; 2015 Sep; 138(3):656-62. PubMed ID: 26115975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.
    Bagnoli M; Balladore E; Luison E; Alberti P; Raspagliesi F; Marcomini B; Canevari S; Mezzanzanica D
    Mol Cancer Ther; 2007 Feb; 6(2):762-72. PubMed ID: 17308072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
    Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Ratner ES; Zhu YL; Penketh PG; Berenblum J; Whicker ME; Huang PH; Lee Y; Ishiguro K; Zhu R; Sartorelli AC; Lin ZP
    Br J Cancer; 2016 Mar; 114(7):777-86. PubMed ID: 26964031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
    Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
    Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.